Primary Cutaneous Mucinous Carcinoma of the Nasolabial Fold: A Case Report Highlighting the GATA3, Estrogen, and Progesterone Receptor Diagnostic Pitfall

鼻唇沟原发性皮肤黏液癌:一例病例报告揭示了GATA3、雌激素和孕激素受体诊断陷阱

阅读:1

Abstract

Primary cutaneous mucinous carcinoma (PCMC) is an exceptionally rare adnexal malignancy of sweat gland origin, with an age-adjusted incidence of approximately 0.04 per 100,000 person-years. We report a rare occurrence of PCMC on the right nasolabial fold of a 55-year-old male. To the best of our knowledge, based on a review of existing literature, this represents the first reported case of PCMC specifically involving the nasolabial fold within the Indian subcontinent. The lesion initially presented as a slow-growing subcutaneous swelling, mimicking benign entities. Histopathological analysis following excisional biopsy revealed neoplastic nests suspended within expansive lakes of extracellular mucin, partitioned by thin fibrous septa. Immunohistochemical (IHC) profiling demonstrated that the tumor cells were strongly positive for CK7 and EMA and also showed diffuse expression of GATA3, estrogen receptor (ER), and progesterone receptor (PR). This specific immunophenotype - particularly the GATA3 positivity - presents a profound diagnostic trap, as it closely mimics the profile of metastatic mucinous carcinoma of the breast. To navigate this GATA3/ER/PR trap, a comprehensive systemic evaluation was mandated, including whole-body positron emission tomography-computed tomography (PET-CT) and mammography, which revealed no evidence of an extracutaneous primary malignancy. This confirmed the diagnosis of PCMC, an indolent but locally aggressive tumor. The patient was managed with wide local excision and remains recurrence-free at one-year follow-up. This case emphasizes that while GATA3, ER, and PR are traditionally associated with mammary origin, their expression in primary cutaneous adnexal tumors is a critical pitfall. Clinicians and pathologists must integrate targeted IHC with rigorous systemic imaging to differentiate PCMC from metastatic disease, ensuring appropriate surgical management and avoiding unnecessary systemic therapy.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。